Daewoong Therapeutics

Bio & Pharma Daewoong wins permission for Nabota in Argentina

South Korea's Daewoong Pharmaceutical Co. announced on Monday that its botulinum toxin Nabota received product approval from Argentina's National Ad...

Bio & Pharma PharmaResearch acquires TuringBio for digital therapeutics

PharmaResearch Co., a South Korean company specializing in regenerative medicine, announced on Wednesday that it acquired TuringBio, an AI-based dig...

Bio & Pharma Daewoong, Indonesia's IPB to co-research on primate

South Korea's Daewoong Pharmaceutical Co. announced on Thursday that it signed a contract with Indonesia's Bogor Agricultural University (Institut P...

IPOs Korean biotech Xcell Therapeutics eyes June IPO

South Korean biotech Xcell Therapeutics Inc., a developer of chemically defined media for in vitro cell culture, is aiming for a junior bourse Kosda...

Bio & Pharma Samsung invests in BrickBio in US

Samsung Group announced on Tuesday that its Life Science Fund has invested in the US-based antibody-drug conjugates (ADC) and gene therapy technol...

Bio & Pharma Daewoong Pharmaceutical digitizes DB of 800 mn chemical compounds

South Korea's Daewoong Pharmaceutical announced on Monday that it has established a drug development system Daewoong AI System (DAISY) which combine...

Bio & Pharma Daewoong gets stem cell facility license in Indonesia

South Korea's Daewoong Pharmaceutical announced on Tuesday that its subsidiary Daewoong Biologics Indonesia has obtained a stem cell Lab Operational...

Bio & Pharma Daewoong exports $92.4 mn Depot injection tech to UAE

South Korea's Daewoong Pharmaceutical announced on Monday that it exported its technology for clinical development and commercialization rights of i...

Bio & Pharma Daewoong Pharm set to export Envlo Tab to Russia, CIS

Daewoong Pharmaceutical, a leading South Korean pharmaceutical company will export its new diabetes drug Envlo Tab. (active ingredient:enavogliflozi...

Bio & Pharma Daewoong Pharma, Merck team up for AI tech for new drug

South Korea's Daewoong Pharmaceutical announced on Tuesday it signed with memorandum of understanding (MOU) with Merck Life Science to build an arti...

Bio & Pharma Daewoong Pharma's GER drug gets product OK from Mexico

South Korea’s Daewoong Pharmaceutical on Wednesday said its gastroesophageal reflux (GER) disease drug Fexuclue (active ingredient fexuprazan ...

Bio & Pharma Daewoong to develop eye drops for diabetic retinopathy

South Korea's Daewoong Pharmaceutical is venturing into the development of a product that can easily treat diabetic retinopathy in the form of ...

Bio & Pharma Daewoong gets patent of Nabota as migraine drug in US

South Korea's Daewoong Pharmaceutical Co. announced on Thursday that it has received a patent from the US Patent and Trademark Office for the use of...

Bio & Pharma Daewoong applies for approval of Envlo in Saudi Arabia

South Korea's Daewoong Pharmaceutical Co. announced on Friday that it has submitted an application for regulatory approval of its new diabetes treat...

Bio & Pharma Daewoong launches GERD treatment Fexuclu in Philippines

South Korea's Daewoong Pharmaceutical announced on Tuesday that it has launched the GERD treatment drug "Fexuclue" (active ingredient: Fexuprazan) i...

Bio & Pharma Daewoong's Nabota exceeds 600,000 customers in US

South Korea's Daewoong Pharmaceutical said on Thursday that its local loyalty program for Nabota (American name: Jeuveau) in the US, a botulinum tox...

Bio & Pharma Celltrion to develop Humira biosimilar oral medication with US firm

South Korea's biopharmaceutical company Celltrion Inc. announced on Monday that it has signed a contract with the US biotech firm Rani Therapeutics ...

Bio & Pharma HanAll, Daewoong to develop Parkinson's treatment with US partner

South Korea's HanAll Biopharma Co. and Daewoong Pharmaceutical on Thursday said they concluded a contract with NurrOn Pharmaceuticals of the US on...

Bio & Pharma Daewoong Pharmaceutical’s cumulative tech exports exceed $870 mn

South Korea’s Daewoong Pharmaceutical said on Friday that it had concluded three technology export agreements for new drugs and new drug candi...

Bio & Pharma Daewoong Pharma to build third botulinum toxin plant for $746 mn

South Korea’s Daewoong Pharmaceutical next year will open a third plant to greatly expand annual output of its botulinum toxin Nabota at a cos...

Bio & Pharma Daewoong to transfer techs for autoimmune disease to US pharma

South Korea's Daewoong Pharmaceutical announced on Friday that it has signed a technology export contract for the clinical development and commercia...

Bio & Pharma Welt gets second digital therapeutic device approval in S. Korea

South Korea's Ministry of Food and Drug Safety announced on Wednesday that it has approved the cognitive therapy software "WELT-I" developed by We...

Bio & Pharma Daewoong Pharma, UK firm to jointly develop autoimmune disease drug

South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday that it has signed a cooperation agreement with Sygnature Discovery, a British ne...

Bio & Pharma Vaxcell-bio's NK cell therapy wins therapeutic approval for liver cancer

South Korean anti-cancer immunotherapy company Vaxcell-Bio Therapeutics announced on Friday that its natural killer (NK) cell therapy, Vax-NK/HCC, h...

Bio & Pharma Daewoong wins approval for GERD treatment Fexuclu in Chile

South Korean pharmaceutical company Daewoong Pharmaceutical announced on Tuesday that it has received marketing authorization from Chile's National ...

Bio & Pharma GC Biopharma to develop mRNA flu vaccine with Canadian pharma

South Korea's GC Biopharma Corp. announced on Thursday that it will start developing a flu vaccine based on messenger ribonucleic acid (mRNA).The dr...

Bio & Pharma Daewoong’s Nabota expands into Germany, Austria

South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday it had launched its botulinum toxin product Nabota in Germany and Austria through i...

Bio & Pharma Daewoong Pharma's Fexuclue safe to use with aspirin: Clinical trials

Daewoong Pharmaceutical Co., a leading South Korean pharmaceutical company, has announced the successful completion of phase 1 clinical trials for...

Bio & Pharma Korea's Daewoong to export diabetes drug Envlo to Brazil, Mexico

South Korea’s Daewoong Pharmaceutical Co. said on Feb. 24 it is set to embark on global sales of Envlo, a new drug for diabetes, by exportin...

Bio & Pharma AIMMED’s Somzz ushers in digital therapeutic device market in Korea

South Korea’s health and drug safety authority has cleared Somzz to treat patients with sleep disorders, a dynamic move that is expected to vi...